Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08

Rhea-AI Filing Summary

Passage BIO, Inc. director Thomas Richard Kassberg received a grant of stock options covering 10,539 shares of common stock. The options have an exercise price of $5.08 per share and expire on May 19, 2036. They vest in full on the earlier of the one-year anniversary of the May 19, 2026 grant date or the company’s 2027 annual stockholders’ meeting, subject to his continued service. Following this award, he holds 10,539 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kassberg Thomas Richard

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	10,539	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 10,539 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 10,539 options Exercise price: $5.08 per share Underlying shares: 10,539 shares +2 more

5 metrics

Options granted 10,539 options Director stock option grant on May 19, 2026

Exercise price $5.08 per share Strike price for director stock option

Underlying shares 10,539 shares Common stock underlying the options

Expiration date May 19, 2036 Option term for director grant

Holdings after grant 10,539 options Total derivative holdings following transaction

Key Terms

Director Stock Option (right to buy), vests in full, Annual Meeting of its stockholders, exercise price, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)""

vests in full financial

"The stock option vests in full on the earlier of"

Annual Meeting of its stockholders financial

"the date of the issuer's 2027 Annual Meeting of its stockholders"

exercise price financial

"conversion_or_exercise_price: "5.0800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-19T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kassberg Thomas Richard

(Last) (First) (Middle)

ONE COMMERCE SQUARE

2005 MARKET STREET, 39TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Passage BIO, Inc. [ PASG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$5.08	05/19/2026		A		10,539		(1)	05/19/2036	Common Stock	10,539	$0	10,539	D

Explanation of Responses:

1. The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

	/s/ Kathleen Borthwick, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Passage BIO (PASG) director Thomas Richard Kassberg receive in this Form 4?

Thomas Richard Kassberg received a grant of director stock options for 10,539 underlying shares. These options are compensation, not an open-market purchase, and give him the right to buy Passage BIO common stock at a fixed exercise price if they vest.

What is the exercise price of the new Passage BIO (PASG) director stock options?

The granted director stock options have an exercise price of $5.08 per share. This means Kassberg can purchase Passage BIO common shares at $5.08, if and when the options vest and he chooses to exercise them before expiration.

When do Thomas Richard Kassberg’s Passage BIO (PASG) options vest?

The stock options vest in full on the earlier of the one-year anniversary of the May 19, 2026 grant date or Passage BIO’s 2027 Annual Meeting of stockholders. Vesting is contingent on Kassberg’s continuous service to the company through that vesting date.

When do the newly granted Passage BIO (PASG) director stock options expire?

The director stock options expire on May 19, 2036. If Kassberg does not exercise the options by that expiration date, they will lapse and no longer allow him to purchase Passage BIO common shares at the $5.08 exercise price.

How many Passage BIO (PASG) options does Thomas Richard Kassberg hold after this grant?

After the reported transaction, Kassberg holds 10,539 stock options directly. These options relate to an equal number of underlying Passage BIO common shares and represent his derivative position from this specific award as disclosed in the filing.